Evidence map›Paper›PMID 29679254›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up.

Y Ma, Y Pang, W Shu, Y-H Liu, Q-P Ge, J Du, L Li, W-W Gao

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Host-directed therapy for tuberculosis.European journal of medical research · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Y MaBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China.
Y PangBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China.
W ShuBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China.
Y-H LiuBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China.
Q-P GeBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China.
J DuBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China. jdu-sdu@163.com.
L LiBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China. liliang69@tb123.org.
W-W GaoBeijing Chest Hospital, Capital Medical University, Machang Road, No. 97, Beijing, 101149, China. gwwjys@sina.com.
Beijing Chest Hospital · CNCapital Medical University · CNCenter for Tuberculosis Control of Guangdong Province · CN

Funding

National Science and Technology Major Project of China 2008ZX10003-009the National Science and Technology Major Project of China 2008ZX10003-008-02
6 · The paper itself

Abstract

The role of metformin (MET) on treatment effect of diabetic tuberculosis (TB) patients has not been studied in China. Thus, we conducted a retrospective study to investigate whether MET exhibited more efficacy in combination with anti-TB regimens for diabetic TB patients. All patients recruited came from five tuberculosis control and prevention institutes from July 2009 to July 2016 and completed 3 years of follow-up. We used chi-square test or Fisher's exact test to evaluate the demographic characteristics and the frequency of clinical outcome between MET and non-MET group. A total of 58 TB patients with diabetes mellitus (DM), of these 27.6% (16/58) patients in the MET group and 72.4% (42/58) patients in the non-MET group, there was no significant difference in blood glucose level between MET and non-MET group (P = 0.494), in addition, there was a higher proportion of treatment success (93.8 vs. 71.4%) and culture conversions by the end of 2 months (87.5 vs. 71.4%) among MET group; the relapse rates of patients in MET and non-MET group were 6.3% (1/16) and 35.7% (15/42) through a 3-year follow-up (P = 0.045). Our data revealed that the use of MET as a combination drug with existing regimen improved the success rate of anti-TB treatment and reduced the relapse rate in TB patients with DM.

Indexed as

ChinaDiabetes Mellitus, Type 2Drug Therapy, CombinationHumansHypoglycemic AgentsMetforminRetrospective StudiesSecondary PreventionSputumTreatment OutcomeTuberculosis, PulmonaryHypoglycemic AgentsMetforminDiabetes mellitusMetforminMycobacterium tuberculosis

Identifiers

PMID29679254
OpenAlexW2799449989

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.